Upgrade to SI Premium - Free Trial

Veru, Inc. (VERU)

2.32 -0.02 (0.85%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/26/26)

Latest Headlines

Form 4 VERU INC. For: Aug 13 Filed by: BARNETTE K GARY August 17, 2026 4:26 PM - SEC Filing Form 10-Q VERU INC. For: Jun 30 August 10, 2026 8:52 AM - SEC Filing Veru, Inc. (VERU) Tops Q3 EPS by 1c August 10, 2026 8:13 AM - StreetInsider Form 8-K VERU INC. For: Aug 10 August 10, 2026 7:00 AM - SEC Filing Veru posts Q3 loss, reports full enrollment in obesity drug trial August 10, 2026 6:30 AM - StreetInsider Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress August 10, 2026 6:30 AM - Globe NewsWire Veru receives patent allowance for enobosarm and semaglutide combo August 4, 2026 8:30 AM - StreetInsider Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss August 4, 2026 8:30 AM - Globe NewsWire Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th August 3, 2026 8:30 AM - Globe NewsWire Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference July 30, 2026 8:30 AM - Globe NewsWire Veru completes enrollment in Phase 2b obesity combination drug trial July 27, 2026 8:10 AM - StreetInsider Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss July 27, 2026 8:10 AM - Globe NewsWire Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day July 7, 2026 8:30 AM - Globe NewsWire Veru sets up $21.8M at-the-market stock offering July 2, 2026 4:12 PM - StreetInsider Form 8-K VERU INC. For: Jul 02 July 2, 2026 4:09 PM - SEC Filing Form 424B5 VERU INC. July 2, 2026 4:07 PM - SEC Filing Full Article List